UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis

Oncogene, 2015-05, Vol.34 (21), p.2690-2699

2015

Volltextzugriff (PDF)

Proteomic analysis for the early detection and rational treatment of cancer—realistic hope?

Annals of oncology, 2005-01, Vol.16 (1), p.16-22

2005

Volltextzugriff (PDF)

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Annals of oncology, 2020-03, Vol.31 (3), p.369-376

2020

Volltextzugriff (PDF)

Interim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer

Annals of oncology, 2018-10, Vol.29, p.viii292-viii292

2018

Volltextzugriff (PDF)

Proteomics in cancer

Annals of oncology, 2004-01, Vol.15 (suppl-4), p.iv167-iv171

2004

Volltextzugriff (PDF)

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium Department of Defense Prostate Cancer Clinical Trials Consortium study

Prostate cancer and prostatic diseases, 2012-03, Vol.15 (1), p.87-92

2012

Volltextzugriff (PDF)

"Physical Quality and Mycotoxins in Corn Silo, Used in Dairy Cattle Feeding in Tizayuca, State of Hidalgo, Mexico"

Journal of dairy & veterinary sciences, 2017-03, Vol.1 (5)

ME, Posadas

2017

Volltextzugriff (PDF)

Chaotic oscillations in cultured cells : Rat prostate cancer

Cancer research (Chicago, Ill.), 1996-08, Vol.56 (16), p.3682-3688

1996

Volltextzugriff (PDF)

Deep AR suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Annals of oncology, 2020-02, Vol.31 (3), p.369-376

2020

Volltextzugriff (PDF)

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

The oncologist (Dayton, Ohio), 2019-02, Vol.24 (2), p.202-210

2019

Volltextzugriff (PDF)

834PInterim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Supplementation Spent Grain from Waste Brewery in the Diet of Household Ovine System in the State of Mexico

Journal of Fisheries & Livestock Production, 2016, Vol.4 (4)

2016

Volltextzugriff (PDF)

Synthesis and characterization of putrescine-based poly(phosphoester-urethanes)

Journal of biomaterials science. Polymer ed., 1993-01, Vol.4 (5), p.529-543

1993

Volltextzugriff (PDF)

Fluorescence-activated cell sorting (FACS) and immunofluorescence (IF) detection and characterization of circulating tumor cells (CTC) from men with castrate-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.41-41

2011

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS241-TPS241

2010

Volltextzugriff (PDF)

A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consortium study

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.170-170

2011

Volltextzugriff (PDF)

Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.137-137

2011

Volltextzugriff (PDF)

Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2543-2543

2011

Volltextzugriff (PDF)

A phase II trial of gemcitabine(G), capecitabine (C), and bevacizumab (B) in patients (pts) with metastatic renal cell carcinoma (RCC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e16072-e16072

2009

Volltextzugriff (PDF)

Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4527-4527

2010

Volltextzugriff (PDF)

A phase II study of perifosine in androgen independent prostate cancer

Cancer biology & therapy, 2005-10, Vol.4 (10), p.1133-1137

2005

Volltextzugriff (PDF)

A phase I study of testosterone in patients (pts) with early castrate resistant prostate cancer (CRPC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15584-15584

2007

Volltextzugriff (PDF)

A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14646-14646

2006

Volltextzugriff (PDF)

Frontiers in prostate cancer. Telomeres and chaos

Cancer, 1995-04, Vol.75 (S7), p.2027-2035

1995

Volltextzugriff (PDF)

Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3004-3004

2006

Volltextzugriff (PDF)

1 – 25 von 433

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(356)
Mit Volltextzugriff
(309)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis

Proteomic analysis for the early detection and rational treatment of cancer—realistic hope?

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Interim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer

Proteomics in cancer

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium Department of Defense Prostate Cancer Clinical Trials Consortium study

"Physical Quality and Mycotoxins in Corn Silo, Used in Dairy Cattle Feeding in Tizayuca, State of Hidalgo, Mexico"

Chaotic oscillations in cultured cells : Rat prostate cancer

Deep AR suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

834PInterim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer

Supplementation Spent Grain from Waste Brewery in the Diet of Household Ovine System in the State of Mexico

Synthesis and characterization of putrescine-based poly(phosphoester-urethanes)

Fluorescence-activated cell sorting (FACS) and immunofluorescence (IF) detection and characterization of circulating tumor cells (CTC) from men with castrate-resistant prostate cancer (CRPC)

A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC)

A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consortium study

Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC)

Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy

A phase II trial of gemcitabine(G), capecitabine (C), and bevacizumab (B) in patients (pts) with metastatic renal cell carcinoma (RCC)

Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure

A phase II study of perifosine in androgen independent prostate cancer

A phase I study of testosterone in patients (pts) with early castrate resistant prostate cancer (CRPC)

A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma

Frontiers in prostate cancer. Telomeres and chaos

Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab

Suchergebnisse filtern